Lyon Joseph Douglas's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 16, 2026
- Accession no.
- 0001193125-26-393125
- Filed
- Sep 16, 2026, 4:30 PM ET
- Trade date
- Sep 14, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.13M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyon Joseph DouglasCIK 0001817838 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Common Stock | MOption exerciseAcquired | +2,596 | $11.35 | +$29,464.6 | 8,279 | Direct | |
| Sep 14, 2026 | Common Stock | MOption exerciseAcquired | +7,404 | $13.56 | +$100,398.24 | 15,683 | Direct | |
| Sep 14, 2026 | Common Stock | SSaleDisposed | −7,812 | $113.32F3 | −$885,260.53 | 7,871 | Direct | |
| Sep 14, 2026 | Common Stock | SSaleDisposed | −2,188 | $114.12F4 | −$249,686.46 | 5,683 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Common Stock | MOption exerciseDisposed | −2,596 | $0.00 | $0 | 0 | Direct | |
| Sep 14, 2026 | Common Stock | MOption exerciseDisposed | −7,404 | $0.00 | $0 | 4,167 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Accounting & Technology Officer